Estrogen Enhances Susceptibility to Experimental Autoimmune Myasthenia Gravis by Promoting Type 1-Polarized Immune Responses

Laurent Delpy, Victorine Douin-Echinard, Lucile Garidou, Corinne Bruand, Abdelhadi Saoudi and Jean-Charles Guéry

*J Immunol* 2005; 175:5050-5057; doi: 10.4049/jimmunol.175.8.5050
http://www.jimmunol.org/content/175/8/5050

**References**
This article cites 57 articles, 26 of which you can access for free at:
http://www.jimmunol.org/content/175/8/5050.full#ref-list-1

**Subscription**
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Estrogen Enhances Susceptibility to Experimental Autoimmune Myasthenia Gravis by Promoting Type 1-Polarized Immune Responses

Laurent Delpy, Victorine Douin-Echirard, Lucile Garidou, Corinne Bruand, Abdelhadi Saoudi, and Jean-Charles Guéry

Myasthenia gravis (MG) is an organ-specific autoimmune disease caused in most cases by autoantibodies against the nicotinic acetylcholine receptor (AChR). It is now well documented that many autoimmune diseases, including MG, are more prevalent in women than in men, and that fluctuations in disease severity occur during pregnancy. These observations raise the question of the potential role of sex hormones, such as estrogens, as mediators of sex differences in autoimmunity. In the present study, we have analyzed the effect of 17β-estradiol (E2) on the pathogenesis of experimental autoimmune myasthenia gravis (EAMG), an animal model of MG. We show that treatment with E2 before Ag priming is necessary and sufficient to promote AChR-specific Th1 cell expansion in vivo. This time-limited exposure to E2 enhances the production of anti-AChR IgG2a (specific for b allotype; e.g., B6) and IgG2b, but not IgG1, and significantly increases the severity of EAMG in mice. Interestingly, the E2-mediated augmentation in AChR-specific Th1 response correlates with an enhanced production of IL-12 by splenic APCs through the recruitment of CD8α+ dendritic cells. These data provide the first evidence that estrogen enhances EAMG, and sheds some light on the role of sex hormones in immune responses and susceptibility to autoimmune disease in women. The Journal of Immunology, 2005, 175: 5050–5057.
estrangement administration on AChR-specific T and B cell responses and on the outcome of EAMG in mice. We show that hormonal treatment limited to the 3 wk before immunization enhances AChR-specific Th1 cell expansion and anti-AChR IgG2a* (specific for b alleloyp; e.g., B6) and IgG2b production, and significantly increases the severity of EAMG in C57BL/6 (B6) mice. Interestingly, we demonstrate that the E2-mediated increase in AChR-specific Th1 cell development correlates with an enhanced capacity of splenic APCs to produce IL-12 through the recruitment of CD8α+ dendritic cells (DCs). These data provide the first evidence for a role of estrogens in the pathogenesis of EAMG.

Materials and Methods

Mice and hormonal treatment

C57BL/6 (B6) mice were purchased from the Centre d’Elevage R. Janvier and were housed in our animal facilities under specific pathogen-free conditions. Male to 3-mo-old female mice were used in all experiments. For estrogen hormone administration, 3-mm pellets (Innovative Research of America) containing 0.01, 0.1, 0.25, or 2.5 mg of E2 were implanted s.c. on the animal back at 4–5 wk of age. These pellets provide continuous release of a constant level of hormone over a period of 60 days. When indicated, these pellets were removed or replaced by surgical intervention the day of immunization. Serum estrogen levels were measured using a commercially available RIA kit (Beckman-Coulter). All of the protocols used have been approved by our institutional review board for animal experimentation.

Purification of tAChR and induction of EAMG

tAChR was purified from electric organs of Torpedo californica by affinity chromatography on a conjugate of neurotoxin coupled to agarose, as previously described (28). To induce EAMG, 8-wk-old mice were inoculated with 10 µg of tAChR emulsified inIFA (Sigma-Aldrich) in a total volume of 100 µl, injected s.c. in the tail base. Four weeks after the first immunization, mice were boosted with 10 µg of tAChR emulsified inIFA (Sigma-Aldrich) in a total volume of 200 µl, injected in the flanks and at the tail base. Control mice received an equal volume of PBS in CFA (100 µl) orIFA (200 µl).

Measurement of muscle AChR content

Three weeks after the second immunization, the concentration of AChR present in total body musculature was measured in muscle detergent extract by RIA, as previously described (3). Briefly, the frozen carcasses were homogenized, and membrane-bound proteins were extracted with PBS containing 2% Triton X-100 (Sigma-Aldrich). Aliquots (250 µl) of each extract were loaded in triplicate with 2 × 10-6 M [3H]-labeled α-bungarotoxin (Amersham; sp. act. >150 Ci/mmol) incubated overnight with an excess of rat anti-AChR, and precipitated by goat or sheep anti-rat IgG. The concentration of AChR in muscle was expressed as moles of [3H]-labeled α-bungarotoxin precipitated per gram of muscle, and the percentage of mouse AChR contents was calculated by comparison with that in control adjuvant-immunized mice.

RIA for serum anti-mouse AChR Abs

Individual mouse sera were prepared from bleeding collected the day of secondary immunization and 3 wk later when mice were killed to measure muscle AChR loss. The concentration of Abs reactive with mouse AChR was determined in individual sera by RIA, as previously described (29). Briefly, mouse AChR was extracted from leg muscles and labeled with 2 × 10-6 M [3H]-labeled α-bungarotoxin (Amersham). A dilution range of serum samples was incubated overnight with 200 µl of labeled mouse AChR. Ab-AChR complexes were captured by adding an excess of rabbit anti-mouse IgG (Sigma-Aldrich) or protein G (Amersham). The radioactivity of the complexes was measured in a gamma counter. Values of [3H]-labeled α-bungarotoxin-AChR pelleted in the presence of normal mouse serum were subtracted from the assay values. Corrections for interassay variability were made based on serial dilutions of an EAMG standard control serum pool tested in each assay. The Abs titers were expressed as moles of [3H]-labeled α-bungarotoxin binding sites precipitated per liter of serum.

ELISA for anti-tAChR Ab isotypes

Microtiter plates (Falcon 3012; BD Discovery Labware) were coated overnight at 4°C with 1 µg/ml tAChR in PBS and incubated with serial dilutions of individual sera. Bound total IgG and IgG2b were revealed using/5g/ml of tAChR emulsified in CFA (Sigma-Aldrich) in a total volume of 100 µl, injected s.c. in the tail base. Four weeks after the first immunization, mice were boosted with 10 µg of tAChR emulsified inIFA (Sigma-Aldrich) in a total volume of 200 µl, injected in the flanks and at the tail base. Control mice received an equal volume of PBS in CFA (100 µl) orIFA (200 µl).

Measurement of muscle AChR content

Three weeks after the second immunization, the concentration of AChR present in total body musculature was measured in muscle detergent extract by RIA, as previously described (3). Briefly, the frozen carcasses were homogenized, and membrane-bound proteins were extracted with PBS containing 2% Triton X-100 (Sigma-Aldrich). Aliquots (250 µl) of each extract were loaded in triplicate with 2 × 10-6 M [3H]-labeled α-bungarotoxin (Amersham; sp. act. >150 Ci/mmol) incubated overnight with an excess of rat anti-AChR, and precipitated by goat or sheep anti-rat IgG. The concentration of AChR in muscle was expressed as moles of [3H]-labeled α-bungarotoxin precipitated per gram of muscle, and the percentage of mouse AChR contents was calculated by comparison with that in control adjuvant-immunized mice.

RIA for serum anti-mouse AChR Abs

Individual mouse sera were prepared from bleeding collected the day of secondary immunization and 3 wk later when mice were killed to measure muscle AChR loss. The concentration of Abs reactive with mouse AChR was determined in individual sera by RIA, as previously described (29). Briefly, mouse AChR was extracted from leg muscles and labeled with 2 × 10-6 M [3H]-labeled α-bungarotoxin (Amersham). A dilution range of serum samples was incubated overnight with 200 µl of labeled mouse AChR. Ab-AChR complexes were captured by adding an excess of rabbit anti-mouse IgG (Sigma-Aldrich) or protein G (Amersham). The radioactivity of the complexes was measured in a gamma counter. Values of [3H]-labeled α-bungarotoxin-AChR pelleted in the presence of normal mouse serum were subtracted from the assay values. Corrections for interassay variability were made based on serial dilutions of an EAMG standard control serum pool tested in each assay. The Abs titers were expressed as moles of [3H]-labeled α-bungarotoxin binding sites precipitated per liter of serum.

ELISA for anti-tAChR Ab isotypes

Microtiter plates (Falcon 3012; BD Discovery Labware) were coated overnight at 4°C with 1 µg/ml tAChR in PBS and incubated with serial dilutions of individual sera. Bound total IgG and IgG2b were revealed using
cells are mostly directed against the immunodominant epitope of the protein contained in the sequence 146–162 of the tAChR α-subunit present by I-A<sup>B</sup> MHC class II molecules. As shown in Fig. 1, A and D, the proliferative response of CD4 T cells specific for tAChR or its immunodominant epitope α146–162 was strongly enhanced in mice treated with 0.1–2.5 mg of E2 pellets, whereas administration of 0.01 mg of pellets had no effect on T cell responsiveness. This increased lymphoproliferative response in E2-treated mice was associated with a dramatic up-regulation of IFN-γ production (Fig. 1, B and E). By contrast, IL-4 and IL-5 were not detected in all groups, and IL-10 production was similar in placebo- and E2-treated mice (Fig. 1, C and F, and data not shown). Because optimal effect of E2 was observed with pellets ranging from 0.1 to 2.5 mg, the intermediate dose of E2 (0.25 mg) was subsequently used throughout the study. To test whether E2 induces qualitative changes in the specificity of tAChR-reactive CD4 T cells, the T cell response to a set of 16-mer peptides overlapping by 12 aa encompassing the extracellular domain of tAChR α-subunit (region 1–210) was tested. We found that tAChR-specific CD4 T cell repertoire was mainly directed against the immunodominant determinant contained in the sequence α146–162 (data not shown).

**Limited exposure to E2 before priming is necessary and sufficient to promote optimal tAChR-specific Th1 cell expansion in vivo**

To determine the optimal condition of E2 administration for the induction of an enhanced Ag-specific Th1 cell response in vivo, we first evaluated whether the presence of the hormone at the time of induction of an enhanced Ag-specific Th1 cell response in vivo, we show that limited exposure to E2 during 3 wk before priming was required (Fig. 2A). To test this, E2 pellets were implanted in mice 3 wk before priming and surgically removed at the time of immunization, resulting in a rapid drop of hormone level to basal values (Fig. 2B). In these mice, E2 levels were already dramatically decreased (from 766.6 to <15 pg/ml) by day 3 following removal of hormone pellets (data not shown). Results in Fig. 2, C–E, show that limited exposure to E2 during 3 wk before priming was sufficient to induce an enhanced production of the type 1 cytokines IFN-γ and TNF-α, as well as IL-6, by CD4 T cells specific for tAChR protein or α146–162 peptide (Fig. 2, C–E, and data not shown). In contrast, E2 administration at the time of immunization did not increase Ag-specific T cell responses (Fig. 2, C–E).

Next, we evaluated whether up-regulation in type 1 cytokine production was due to an enhanced expansion of Ag-specific CD4 T cells in draining lymph nodes in vivo. In Fig. 3A, we show that the frequency of memory/effector CD4<sub>+</sub>CD62L<sup>low</sup> CD4 T cells was significantly increased (p = 0.011) in LNC from E2-treated mice. To quantify Ag-specific effector Th1 cells ex vivo, lymph node CD4 T lymphocytes were stimulated with α146–162 peptide for 8 h and stained for intracellular cytokines. Data in Fig. 3B show that there was an overall 3-fold increase in the frequency of IFN-γ- or TNF-α-producing α146–162-specific CD4 T cells in E2-treated mice. In contrast, the Th2 cytokines IL-4 and IL-5 were undetectable in the culture supernatants or by intracellular staining (data not shown). Therefore, the E2-dependent enhanced production of type 1 cytokines is due to an increased expansion of Ag-specific memory/effector Th1 cells in vivo.

**Limited exposure to E2 before primary immunization to tAChR enhances EAMG and complement-fixing anti-AChR Abs**

To analyze the effect of estrogen administration on EAMG development, mice were treated with E2 during the 3 wk before the primary immunization with tAChR in CFA and challenged with the same Ag in IFA 1 mo later. Mice were killed 3 wk after the

---

**FIGURE 1.** Dose-dependent effect of E2 administration on AChR-specific CD4 T cell proliferation and IFN-γ production. Normal 4- to 5-wk-old B6 female mice were implanted with pellets containing various doses of E2 (0.01 mg/pellet, Δ; 0.1, 0.25, and 2.5 mg/pellet, light gray circles, , and ○, respectively) or left untreated (□). At 8 wk of age, mice were immunized s.c. in the hind footpads with 5 × 10<sup>5</sup> cells/well of [H]tAChR during the last 12 h of culture (A and D), IFN-γ (B and E) and IL-10 (C and F) secretion was tested by ELISA in 72-h LNC (6 × 10<sup>5</sup> cells/well) culture supernatants.

**FIGURE 2.** E2 administration before immunization is necessary and sufficient to enhance AChR-specific Th1 responses. A, B6 female mice were either left untreated (--) or implanted with 0.25 mg of E2 pellets at 5 wk of age. Three weeks later, E2 pellets were surgically removed from the E2 “5–8 wks” group. An additional group of mice was implanted with E2 pellets the day of immunization at 8 wk of age (E2 “after 8 wks”). All mice were immunized as described in Fig. 1. B, Serum was collected the day of immunization and the following 3 and 9 days and assessed for 17β-estradiol quantification by RIA (N.D., not detectable; <15 pg/ml). Draining LNC were harvested 9 days after immunization and stimulated as described in Fig. 1. IFN-γ (C), TNF-α (D), and IL-6 (E) production was assessed in 72-h culture supernatants by ELISA. Untreated mice are represented by □ and ○, 3-wk E2-treated mice (with pellet removal the day of immunization) by △ and ●, and mice treated with E2 the day of immunization by ★ (p < 0.001; **, p < 0.01; ***, p < 0.001).

---

The above text provides a detailed description of the experimental setup and results, including the effects of estrogen administration on immune responses and disease progression in a mouse model of autoimmune myasthenia gravis (A-Mg). The study reveals that estrogen enhances EAMG and the production of complement-fixing anti-AChR antibodies, with optimal results achieved when estrogen administration precedes primary immunization with tAChR in adjuvant, and is necessary but not sufficient when administered at the time of immunization.
FIGURE 3. E2 administration induces preferential expansion of memory/effector CD4 T lymphocytes. Normal 4- to 5-wk-old B6 mice were implanted with 0.25 mg of E2 pellets or left untreated. At 8 wk of age, E2 pellets were removed and mice were immunized as described in Fig. 1. Draining LNC were harvested 9 days later and stained for CD4, CD44, and CD62L (A). B, LNC were stimulated for 8 h with peptide α146–162 (3 μM) plus soluble anti-CD28 (5 μg/ml) and stained for surface CD4 and intracellular cytokines (IFN-γ and TNF-α), as described in Materials and Methods. Analysis was performed on 3 × 10^6 CD4+ cells and expressed as mean ± SEM of four mice per group. Data are from one representative experiment of two performed.

FIGURE 4. E2 administration before immunization enhances severity of EAMG. Normal 4- to 5-wk-old B6 female mice were implanted with 0.25 mg of E2 pellets or left untreated. In 8-wk-old mice, E2 pellets were removed and EAMG induction was performed by immunizations with 10 μg of tAChR, as described in Materials and Methods. Twenty-one days after the second immunization, mice were killed and endogenous AChR quantification was measured by RIA on whole body musculature. Data were expressed as the percentage of the AChR content of CFA-immunized age-matched control mice (A). The concentration of IgG Abs reactive with mouse AChR was determined by RIA in individual sera from days 0 and 21 after the second immunization (B). Data are pooled from two experiments; a p value <0.05 was considered as significant (*, p = 0.017; **, p < 0.01; ***, p < 0.001).

FIGURE 5. Limited exposure to E2 enhances the production of complement-fixing anti-tAChR Ab isotypes. Normal 4- to 5-wk-old B6 mice were implanted with 0.25 mg of E2 pellets or left untreated. At 8 wk of age, E2 pellets were removed and mice were immunized in the tail base with 5 μg of tAChR in CFA. Sera were collected 14 days after immunization, and the concentration of total IgG (A), IgG2a (B), IgG2b (C), and IgG1 (D) reactive with tAChR was determined by ELISA in individual sera from untreated (□) or E2-treated (■) mice. Data are pooled from three experiments and expressed as arbitrary U/ml serum. A p value <0.05 was considered as significant (*, p = 0.013 for y2b isotypes; **, p < 0.01).

Enhanced tAChR-specific Th1 expansion is associated with an increased IL-12 production by splenic APCs in E2-treated mice

To further investigate the basis for the E2-mediated increase in EAMG susceptibility, we then analyzed the spleen cell populations 14 days after tail base immunization with tAChR. As shown in Table I, E2-pretreated mice exhibited a significant increase in spleen cellularity as compared with placebo-treated mice (respectively 150 × 10^6 and 105 × 10^6 cells/spleen). This was mainly due to an E2-mediated 1.5-fold increase in the number of B cells. In contrast, absolute numbers of CD4+ and CD8+ T lymphocytes were not altered by E2 treatment (Table I). Consistent with our data in Fig. 2, AChR-specific Th1 response by splenic CD4 T cells was also strongly enhanced in E2-treated mice (data not shown).
Therefore, both enhanced expansion of B cells and production of type 1 cytokines by AChR-specific CD4 T cells occur in the spleen and correlate with the enhanced production of anti-tAChR IgG2ab and IgG2b isotypes in E2-pretreated mice.

We also examined whether estrogen administration affects the splenic APC populations and their capacity to secrete the Th1-promoting cytokine IL-12. Interestingly, we found that the E2-mediated up-regulation of IFN-γ production by Ag-specific CD4+ T cells was correlated with an increased capacity of splenic APCs, most likely DCs, to secrete IL-12 upon in vitro stimulation with SAC plus IFN-γ (Fig. 6A). Within the multiple DC subsets, the lymphoid DC subtype characterized by expression of lineage-specific markers CD11c and CD8α (CD11c<sup>+</sup>CD8α<sup>−</sup>CD11b<sup>+</sup>) has been shown to produce higher amounts of IL-12 and to better trigger the development of Th1 cells as compared with CD11b<sup>+</sup> myeloid DCs (35, 36). In the present study, we observed that the frequency of CD8α<sup>+</sup>CD11c<sup>+</sup> DCs was higher in splenocytes from E2-treated mice than control mice (Fig. 6B, <i>p</i> < 0.001). In addition, we found that compared with control mice, spleens from E2-pretreated mice exhibited a 1.5- and 2-fold increase in the absolute number of splenic DCs and CD8α<sup>+</sup> DCs, respectively (Table I and data not shown). Altogether, these data indicate that the E2-mediated increase in AChR-specific Th1 response is associated with an enhanced capacity of splenic APC to produce IL-12 through the recruitment of CD8α<sup>+</sup> DC.

**Discussion**

In the present study, we have analyzed whether exposure to estrogen modulates development of autoimmune myasthenia gravis through action on AChR-specific T and B cell responses. We show that E2 treatment enhances AChR-specific CD4<sup>+</sup> T cell expansion in vivo and their capacity to produce type 1 cytokines, such as IFN-γ and TNF-α, as well as IL-6, but not the Th2 cytokines IL-4, IL-5, and IL-10. These data are in agreement with our previous findings showing that E2 administration resulted in amplification of Ag-specific Th1 cell responses through estrogen receptor α (ERα) expression in hemopoietic cells (37). Interestingly, we show in this study that the promoting effect of E2 on AChR-specific Th1 response was maintained in the absence of hormone supplementation during the development of the immune response. Thus, a sustained increase in serum E2 levels 3 wk before immunization was necessary and sufficient to enhance AChR-specific immunity. This exacerbation of AChR-specific Th1 responses mediated by E2 presensitization was lost in ERα-deficient mice (our unpublished data). Using this protocol of time-limited exposure to E2, we further observed an increased severity of EAMG development associated with enhanced production of anti-tAChR Abs of IgG2a<sup>+</sup> and IgG2b isotypes. Such IgG subclasses have been shown previously to play an important role in susceptibility to EAMG in mouse (8, 34, 38, 39). Our data support the hypothesis that estrogens, as sex-specific factors, may be responsible for the higher susceptibility of women to MG through an enhancing effect on the development of autoimmune T and B cell responses to AChR.

Concerning the role of estrogens on polarization of T cell responses, it has been shown in vitro that, depending on the dose of hormone, E2 could modulate both pro- and anti-inflammatory activities of human T cell clones (40). Thus, it has been hypothesized that the response to estrogens might be biphasic with high levels driving a Th2-polarized cytokine secretion pattern and inhibiting autoimmunity, whereas low levels could promote Th1 immunity and susceptibility to cell-mediated autoimmune diseases (20). However, our data challenge this hypothesis and show that treatment with low to high doses of E2 increases AChR-specific Th1 cell response in vivo. Indeed, we provide evidence that over a wide dose range of E2 corresponding to estrus (0.1 mg of E2 pellet) to pregnancy levels (2.5 mg of E2 pellet) (27, 41), a strong enhancement of Ag-specific Th1 responses was observed. By contrast, type 2 cytokines were not up-regulated, demonstrating a selective increase in Th1 responsiveness. Our data contrast with previous experiments, showing that administration of similar doses of E2

---

**Table I. Analysis of spleen cell populations in control and E2-treated AChR-immunized mice**

<table>
<thead>
<tr>
<th>Value</th>
<th>Fold Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>E2</td>
</tr>
<tr>
<td>Total&lt;sup&gt;a&lt;/sup&gt;</td>
<td>104.8 ± 5.8</td>
</tr>
<tr>
<td>CD19&lt;sup&gt;b&lt;/sup&gt;</td>
<td>59.0 ± 4.5</td>
</tr>
<tr>
<td>CD4&lt;sup&gt;b&lt;/sup&gt;</td>
<td>22.5 ± 1.1</td>
</tr>
<tr>
<td>CD8&lt;sup&gt;b&lt;/sup&gt;</td>
<td>12.1 ± 0.5</td>
</tr>
<tr>
<td>CD11c&lt;sup&gt;b&lt;/sup&gt;</td>
<td>2.2 ± 0.2</td>
</tr>
</tbody>
</table>

<sup>a</sup>Data are pooled from two experiments (<i>n</i> = 13), and statistical significance was determined by two-tailed Student’s t test (NS: <i>p</i> > 0.05).<br>
<sup>b</sup>Normal 4- to 5-wk-old B6 mice were implanted with 0.25 mg of E2 pellets or left untreated. At 8 wk of age, E2 pellets were removed and mice were immunized in the tail base with 5 µg of tAChR in CFA. Spleen cells were harvested 14 days later, and absolute number of cells was expressed as mean ± SEM per spleen (<i>x</i> 10<sup>5</sup>).
(2.5–0.36 mg) 1 wk before immunization inhibits type 1 cytokine production and induces a modest increase in IL-10 production by Ag-specific CD4 T cells (27, 42). Together, these data emphasize the importance of the timing of E2 administration rather than the dose of hormone on T cell polarization. Indeed, we further demonstrated that E2 administration 3 wk before priming was required for the induction of enhanced Ag-specific Th1 cell responses. By contrast, starting hormonal treatment at the time of immunization had little, if any, effect on the establishment of T cell responses. This observation may also explain previous experiments showing that estrogen administration during the course of EAMG in rats had no effect on disease severity (43).

Th1 differentiation is driven by signaling pathways emanating from both TCR and IL-12R (44), and the involvement of IL-12 production by professional APCs such as DCs is essential for fixation, amplifying, and maintaining Th1 cell effector functions (45). Indeed, we showed that E2-mediated up-regulation of IFN-γ production by Ag-specific T cells correlated with an increased capacity of splenic APCs to secrete IL-12 upon in vitro stimulation with SAC plus IFN-γ. Furthermore, the enhancement of Ag-specific Th1 response induced by E2 administration was completely abolished in IL-12Rβ2−/− mice (our unpublished data), demonstrating that the E2-mediated increase in Ag-specific Th1 cell development required a functional IL-12/IL-12R signaling pathway. Thus, it is likely that the higher propensity of E2-treated mice to mount Th1 cell responses in vivo could be due to the recruitment in situ of a phenotypically and functionally distinct population of DC. In support of this, it has been recently shown that estrogens were needed for the optimal development of DCs from bone marrow precursors in vitro (46). The requirement for estrogens during DC differentiation suggests a mechanism by which E2 levels in peripheral tissues might modulate both number and functional properties of DC in vivo, thereby influencing immune responses. Indeed, splenic DC numbers were increased in E2-treated mice, and this increase seems to affect preferentially CD8α+ DCs that have been shown to secrete higher amounts of IL-12 (35, 47). However, we cannot rule out that these quantitative and phenotypic changes in splenic DC populations might reflect secondary events due to an enhanced production of T cell-derived cytokines upon immunization of E2-treated mice, resulting in an increased recruitment and/or maturation of CD8α+ lymphoid DCs in T cell zones, as previously suggested (47).

Even though MG and EAMG are mediated by autoantibodies, CD4 T cells play a crucial role in the control of the autoimmune process. Using cytotoxic knockout mice, it has been shown that IFN-γ and IL-12 were necessary for the development of EAMG, whereas IL-4 was dispensable (6–8). Although these data underline the importance of Th1 cytokines in the pathogenesis of this Ab-mediated autoimmune disease, it has also been shown that IL-5 and IL-10 could influence EAMG development (9–11). However, in our study, a role for such type 2 cytokines is unlikely because their production by AChR-specific CD4 T cells was not enhanced by E2 treatment. Thus, estrogens may contribute to the susceptibility to EAMG by promoting Th1 cell development in vivo and the subsequent development of pathogenic autoreactive B cells. Indeed, the induction of strongly Th1-polarized immune responses by IL-12 administration in vivo was found to provide optimal conditions for the development of EAMG both in mice (8, 38) and rats (3).

Interestingly, the enhanced CD4 T cell response measured in spleen from E2-presensitized AChR-immunized mice was also associated with an increase in cellularity that was mainly due to B cells. Such observation contrasts with previous studies showing decreased B cell lymphopoiesis in E2-treated mice (48). This effect was mainly observed in bone marrow of normal nonimmunized mice (48). Thus, the increased splenic B cell number reported in this work could be due to enhanced B cell proliferation induced by Ag-specific CD4 T cells. Furthermore, the drop in serum estrogen levels following E2 pellet removal could also increase B lymphopoiesis. Indeed, estrogen deficiency has been shown to stimulate B lymphocyte development in mice (49). Thus, in the spleen, polarized Th1 cells could provide help to AChR-specific B cells and support Ab class switching toward complement-fixing IgG2a and IgG2b (6–8, 50). Because IL-6 is crucial for both the differentiation of activated B cells into plasma cells and the development of EAMG (51), the 3- to 4-fold increased serum level of these pathogenic IgG2a and IgG2b isotypes found in E2-presensitized mice could be due to the increased production of this cytokine and could reflect a higher propensity to B cells to give rise to postswitch plasmocytes. A role for estrogens as triggers of immune complex-mediated autoimmune diseases has been well documented in murine lupus. It has been shown that E2 treatment of NZB/NZW F1 lupus-prone mice accelerates Ab-mediated glomerulonephritis, resulting in earlier disease onset and increased mortality (21). Some molecular mechanisms for the estrogen-promoting effect on this autoimmune disease have recently been provided. E2 treatment of nonautoimmune mice transgenic for the H chain of an anti-DNA Ab led to the rescue from deletion of a population of autoreactive B cells due to enhanced Bcl2 expression (52–54). Likewise, E2 administration has been shown to increase plasma cell number and to enhance autoantibody production in B6 mice (55). According to these data, we could not exclude that in our study both enhanced survival of autoreactive B cells and increased Th1-driven AChR-specific Ab response are at work in the E2-mediated exacerbation of EAMG.

In this study, the reported deleterious effect of E2 treatment on EAMG underlines the complexity of the role of estrogens in autoimmunity. We and others have also demonstrated that estrogens could be associated with clinical improvement of cell-mediated autoimmune diseases such as EAE or collagen-induced arthritis (26, 27, 31). Using irradiation bone marrow chimeras, we have shown recently that the beneficial effect of E2 on EAE did not involve ERα signaling in hemopoietic cells. These data indicate that ERα expression in endothelial cells or in other tissues, such as CNS-resident microglia, may mediate the protective effect of E2 on EAE (31). Therefore, the ERα-driven effects of E2 on hemopoietic vs nonhemopoietic tissues could be partly responsible for the paradoxical effects of estrogens on Th1-associated autoimmune diseases. Our current hypothesis is that E2-mediated protection on autoimmunity could be dependent on the type of effector arms involved in immune responses. Because cell-mediated immune responses have been ultimately implicated in the pathogenesis of RA or MS, we hypothesize that E2 might dampen the inflammatory phase, leading to tissue injury in these autoimmune diseases by preventing inflammatory leukocyte recruitment in target organs. This phenomenon might be dependent on the maintenance of high plasma levels of E2 such as those found during late pregnancy. Reduction in estrogen level would result in disease reappearance or exacerbation, a situation that has been reported in MS and RA patients following delivery (19, 56–58). By contrast, estrogen would not be predicted to have protective effects in autoimmune diseases in which autoantibody production is central to much of tissue damage. This would explain why immune complex- or Ab-mediated autoimmune diseases such as SLE or MG, respectively, could worsen during pregnancy (20).

In conclusion, our study provides the first evidence that estrogens may contribute to the susceptibility to EAMG by promoting
AChR-specific Th1 cell expansion and the development of patho-
genic autoreactive B cells. Understanding how E2 operates in modulating innate and adaptive immunity in vivo may provide new insights into the mechanisms by which sex-linked factors affect immunity and susceptibility to autoimmune diseases in women. In addition to its obvious relevance to early onset MG, these data could also have wide-ranging implications for the use of either estrogen or anti-estrogen therapies in other autoimmune diseases.

Acknowledgments

We thank C. Courue and the animal facility staff of the Institut Fédératif de Recherche 30 for their skillful technical assistance. We also thank Dr. A. Krust (Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France) for her help in testing serum estradiol concentrations.

Disclosures

The authors have no financial conflict of interest.

References

tor-reactive T cells in myasthenia gravis: evidence for the involvement of dif-
7. Balasa, B. C., D. Jeng, J. Lee, P. Christadoss, and N. Sarvetnick. 1998. The Th2 cytokine IL-4 is not involved for the progression of antibody-dependent autoim-
roimmunol. 125: 51–58.
roimmunol. 125: 51–58.


